Exercise capacity in patients with left heart failure is closely related to the performance of the right ventricle and the pulmonary circulation. To determine the significance of changes in pulmonary resistance during longterm vasodilator therapy, hemodynamic studies were performed before and after 1 to 3 months of treatment with captopril in 75 patients with severe chronic left heart failure.
after 1 to 3 months, but symptomatic hypotension occurred more frequently in Group II than in Group I (3~ versus 8%) (p < 0.005).
These findings indicate that changes in the pulmonary circulation modulate alterations in both right and left ventricular performance during the treatment of patients with left heart failure. Hyponatremic patients are likely to experience symptomatic hypotension with captopril because they are limited in their ability to increase cardiac output as a result of an inadequate pulmonary vasodilator response to the drug.
(J Am Coll CardioI1985; 6:635-45) renal and cerebral blood flow and favorably modifies salt and water homeostasis (4) (5) (6) (7) (8) (9) , and these actions may contribute significantly to the therapeutic effects of the drug. Because excessive systemic resistance has been regarded as the principal hemodynamic abnormality in patients with heart failure, previous studies of captopril have focused largely on its effects on the systemic vasculature and left ventricle, and little attention has been given to its actions on the pulmonary circulation. Recent evidence (10, II) indicates, however, that exercise capacity in patients with left heart failure is more closely related to the performance of the right ventricle than that of the left ventricle, because the pulmonary circulation fails to dilate significantly in these patients during exertion and may thereby limit any increase in cardiac output that might be expected to follow a decrease in resistance to left ventricular ejection. Therefore, treat-
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ment with systemic vasodilator drugs may not increase forward flow and exercise capacity if the decrease in pulmonary resistance fails to match the decrease in systemic resistance (12) , but fortunately, most vasodilating agents dilate the systemic and pulmonary circulations to a similar degree (13) (14) (15) . Such a balanced effect may not occur during converting enzyme inhibition, however, because angiotensin exerts little direct constrictor effect on the pUlmonary circuit in doses that markedly affect systemic vessels (16) (17) (18) (19) (20) . Therefore, short-term treatment with captopril in patients with heart failure produces decreases in pulmonary resistance that are less marked than the concomitant decreases in systemic resistance (21, 22) . Whether this hemodynamic discordance persists during long-term therapy with the drug, however, remains unknown. In the present study we evaluated the long-term changes in pulmonary arteriolar resistance in patients with severe left ventricular failure treated with captopril to determine their hemodynamic and clinical significance and to postulate potential mechanisms that may underlie the occurrence of these changes.
Methods
Study patients. The study group consisted of 75 consecutive patients with severe chronic heart failure treated with captopril who underwent invasive hemodynamic studies during short-and long-term treatment with the drug. All patients had dyspnea and fatigue at rest or on minimal exertion despite optimal therapy with digitalis and diuretic drugs; all had a left ventricular ejection fraction less than 30% by radionuclide angiography. There were 55 men and 20 women, aged 28 to 83 years (mean 64). The cause of heart failure was ischemic heart disease in 46 patients, primary dilated cardiomyopathy in 23 patients and primary mitral or aortic valve regurgitation, or both, in 6 patients, 3 of whom had undergone valve replacement surgery. No patient had had an acute myocardial infarction within 4 weeks or an acute exacerbation of symptoms of heart failure within 2 weeks.
Hem9dynamic assessmt!nt. Each patient received captopril under controlled study conditions for 1 to 3 months, during which time the hemodynamic effects of the drug were assessed by right heart catheterization performed before initiation of therapy and at the end of the treatment period. At the beginning of the trial, for at least 5 days before administration of captopril, doses of digoxin and diuretic drugs remained constant, all previous vasodilator drugs were discontinued and patients maintained stable weight while consuming a 2 g sodium diet. After completion of this initial stabilization period, right heart catheterization and arterial cannulation were performed for measurement of intracardiac and systemic pressures, respectively (9, 15, 21) . Left ventricular filling pressure was estimated from the mean pulmonary capillary wedge pressure (71 patients) or from the pulmonary artery diastolic pressure after its identity with wedge pressure was established (4 patients). Thermodilution cardiac outputs were determined in triplicate by a bedside cardiac output computer using iced injectate.
Drug administration. The following hemodynamic variables were measured repeatedly for at least 2 hours (with a variation of less than 10%) to ensure stability of the pretreatment hemodynamic state before drug administration: mean arterial pressure, heart rate, left ventricular filling pressure, mean right atrial pressure and cardiac output. Each patient then received an initial dose of 25 mg of captopril orally followed by long-term therapy with the drug. Because the response to converting enzyme inhibition is not dose dependent (23, 24) , the doses of captopril prescribed for long-term treatment were based on each patient's renal function: patients with a serum creatinine concentration less than 2.0 mg/dl generally received 150 to 300 mg orally daily, whereas patients with higher concentrations received 75 to 150 mg orally daily. For the next 1 to 3 months, doses of digitalis, diuretic agents and captopril remained unaltered, and a 2 g sodium diet was maintained. At the end of the treatment period, patients were again hospitalized for a 5 day stabilization period, after which right heart catheterization and arterial cannulation were again performed to assess the long-term response to treatment. The protocol for the second evaluation was identical in all respects to that of the first study.
During the first hemodynamic study, all hemodynamic variables determined during the baseline period were reassessed every 30 minutes for 3 hours after administration of the first 25 mg dose of captopril; during the second hemodynamic study, these variables were measured at identical intervals after administration of the same dose of captopril each patient had been receiving during the previous 1 to 3 months.
Additional pharmacologic testing was performed in selected patients during the second hemodynamic study after the long-term effects of captopril had been assessed. In nine patients in whom captopril produced minimal changes in pulmonary arteriolar resistance, nitroglycerin (0.4 mg sublingually) was administered 30 to 60 minutes after the peak effect of captopril was observed, and aU hemodynamic variables were reassessed every 2 to 5 minutes for 20 to 30 minutes.
Biochemical and clinical determinations. Blood samples were collected just before initiation of captopril therapy for determination of blood urea nitrogen and serum creatinine concentration in all patients and for measurement of plasma renin activity in 71 of the 75 patients; these variables were reassessed during the second hemodynamic study 90 minutes after captopril administration. All samples were drawn at the same time of day, while patients were consuming a 2 g sodium diet, and after at least 4 hours in the supine position.
Changes in the clinical status of each patient after 1 to 3 months of treatment with captopril were assessed in relation to symptoms of dyspnea and fatigue at rest and exercise tolerance. Because all patients had symptoms at rest or on minimal exertion, formal exercise testing was not performed.
Data analysis. Mean systemic and pulmonary artery pressures were determined by electronic filtration. Derived hemodynamic variables were calculated as follows: cardiac index (CI) = CO/body surface area (liters/min per m2); stroke volume index (SVI) = CIIHR (beats/min); LV stroke The hemodynamic effects of captopril during the first and second hemodynamic studies were assessed at its peak effect on left ventricular filling pressure and mean systemic arterial pressure (60 ± 30 minutes after drug administration). The hemodynamic responses seen during short-and Patients were then classified into three groups according to the hemodynamic responses observed during long-term treatment: Patients in Group I showed predominant pulmonary vasodilation, as evidenced by a percent decrease in pulmonary arteriolar resistance (PAR) that was greater than the percent decrease in systemic vascular resistance (SVR) (% ~ PAR/% ~ SVR > 1.0) with both variables decreasing by at least 20%; this definition is similar to those we and other investigators utilized to identify an active pulmonary vasodilator response in previous studies (25) (26) (27) . Patients in Group II showed predominant systemic vasodilation, as evidenced by a % ~ PAR/% ~ SVR less than 1.0, with both variables decreasing by at least 20%. Patients in whom neither systemic vascular resistance nor pulmonary arteriolar resistance decreased at least 20% during long-term treatment were identified as Group III.
Statistics. The control hemodynamic, biochemical and hormonal variables before captopril administration in the three groups were compared by one-way analysis of variance followed by the t test for independent variables to differentiate among significant responses. Qualitative differences among the three groups were assessed by the chi-square statistic. The long-term biochemical and hormonal effects of captopril were compared with pretreatment values within each group by the t test for paired data and among the three groups by analysis of variance. The hypotheses that two variables were related were tested by least squares linear regression analysis. The responses to nitroglycerin in nine patients were assessed and compared with the effects of captopril in these patients by a repeated measures analysis of variance procedure similar to tha~ utilized for Table 1 . All group data are expressed as mean ± SEM.
Results
Overall short-and long-term hemodynamic responses (Table 1) . In our 75 patients with severe chronic heart failure, captopril produced significant increases in cardiac index, stroke volume index and left ventricular stroke work index and significant decreases in left ventricular filling pressure, mean pulmonary and systemic arterial pressures, mean right atrial pressure and systemic and pulmonary resistances during short-and long-term therapy (p < 0.01) without significant changes in right ventricular stroke work index. During the course of treatment, we noted a progressive increase in left ventricular stroke work index and a JACC Vol. 6. No.3
September 1985: progressive decrease in left ventricular filling pressure, mean pulmonary artery pressure and mean right atrial pressure (p < 0.05 to 0.01), whereas other hemodynamic variables generally remained at levels similar to those seen after the first dose of the drug.
After the first doses of captopril, the magnitude of the decrease in pulmonary arteriolar resistance was substantially less than the magnitude of the qecrease in systemic vascular resistance (15 versus 28%, p < 0.001), and this discordance persisted during long-term treatment with the drug. There was a significant relation between the magnitude of the decrease in pulmonary arteriolar resistance after the first dose of captopril and the decrease in this variable after 1 to 3 months of therapy in individual patients (r == 0.57, P < 0.001).
. Intergroup differences in the hemodynamic response to captopril (Table 2 ). Patients in Groups I, II and III were similar with respect to all pretreatment hemodynamic variables, except that patients in Group III had a significantly lower mean pulmonary artery pressure and pulmonary arteriolar resistance than did patients in Groups I and II (whose pretreatment hemodynamic state was similar with respect to all measured variables). The hemodynamic responses to long-term captopril therapy in patients in Groups I and II are shown and compared in Figures 1 to 3. In patients in The difference noted between Groups I and II with respect to cardiac index was not due to different effects of captopril on heart rate in the two groups; heart rate decreased significantly (p < 0.001) and similarly in both cohorts (87.2 ± 2.8 to 76.3 ± 2.8 beats/min in Group I and 88.0 ± 3.2 to 76.2 ± 3.1 beats/min in Group II). Therefore, Left ventricular filling pressures decreased similarly in both groups, but because pulmonary arteriolar resistance decreased more in Group I than in Group II, patients in Group I showed a greater decrease in mean right atrial pressure than did those in Group II ( -8.0 versus -4.1 mm Hg, P < 0.0 I). Although right ventricular stroke work index increased slightly in Group I and decreased slightly in Group II, these changes did not reach statistical significance.
Patients in Group III showed small but significant (p < 0.05) increases in stroke volume index and decreases in left ventricular filling pressure, mean pulmonary artery pressure, mean right atrial pressure and systemic vascular resistance without changes in cardiac index, right or left ventricular stroke work index or pulmonary arteriolar resistance (data not shown). The magnitude of these changes (where significant) was less than the changes seen in Groups I and II for all hemodynamic variables (p < 0.05 to 0.01).
Intergroup differences in the hormonal and clinical response to captopril (Tables 2 and 3 ). Patients in Groups I, II and III were similar with respect to age, sex, cause of heart failure, pretreatment body weight and pretreatment renal function. Pretreatment values for plasma renin activity, however, were significantly higher in patients in Group II (8.7 ± 2.1 ng/ml per h) than in Groups I and III differences among the three groups (by analysis of variance) in the magnitude of captopril-induced changes; with respect to weight and plasma renin activity, the observed significance is the result of changes in Group I that were greater in magnitude than those seen in Groups II and III. C = control; CPT = I to 3 months of captopril therapy.
(3,0 ± 0,6 and 2.5 ± 0.7 ng/ml per h, respectively, both p < 0.05 versus Group II). Accordingly, values for serum sodium concentration were lower in patients in Group II (133.1 ± 0.9 mEg/liter) than in Groups I and III (137.1 ± 0.6 and 136.0 ± 0.6 mEg/liter, respectively; p < 0.01 and 0.05 versus Group II, respectively). Considering only patients in Groups I and II (in whom systemic vascular and pulmonary arteriolar resistance both decreased), we noted a linear but inverse relation between the pretreatment plasma renin activity (PRA) and the ratio of the change in pulmonary to the change in systemic resistance during longterm captopril therapy (PRA versus % d PAR/% d SVR; r = 0.53; P < 0.001) (Fig. 4) . Table 3 . Plasma renin activity increased significantly (p < 0.01) in all three groups of patients; the magnitude of reactive hyperreninemia in patients in Group I ( + 18.7 ± 4.9 ng/ml per h), however, was significantly greater than Figure 4 . Relation between the ratio of the change in pulmonary arteriolar resistance to the change in systemic vascular resistance (% .:l PAR/% .:l SVR) during long-term captopril therapy to pretreatment values for plasma renin activity in individual patients in Groups I and II who showed a decrease in both pulmonary and systemic resistance. (Table 4) . Nine patients in Group II received nitroglycerin 0.4 mg sub lingually 30 to 60 minutes after the assessment of the responses to long-term captopril therapy. Compared with the immediate pretreatment hemodynamic state (30 to 60 minutes after peak captopril effect), nitroglycerin significantly decreased (within 10 minutes) right and left ventricular filling pressures, mean systemic and pulmonary artery pressures and pulmonary and systemic vascular resistances (p < 0.05 to p < 0.01). Compared with the hemodynamic state observed at peak captopril effect, however, only the decrease in mean pulmonary artery pressure (p < 0.05) and pulmonary arteriolar resistance (p < 0.01) was significant, and this pulmonary vascular response occurred without changes in other hemodynamic variables.
Changes in biochemical and hormonal variables in the three groups of patients before and after captopril are shown in

Hemodynamic effects of nitroglycerin in Group II
Discussion
The findings of the present study indicate that changes in pulmonary arteriolar resistance play an important role in determining the long-term hemodynamic and clinical re- analysis of variance. Pre-C = pre-captopril; C-DI = first dose of captopril; C-LT = long-term captopril therapy; Pre-N = before nitroglycerin (30 to 60 minutes after C-LT); Post-N = after nitroglycerin; other abbreviations as in Table 2 .
sponses to captopril therapy in patients with severe chronic left ventricular failure. Despite similar decreases in left ventricular filling pressure and systemic vascular resistance, patients who showed substantial pulmonary vasodilation (Group I) experienced greater increases in cardiac index, stroke volume index and left ventricular stroke work index than did patients who demonstrated predominant systemic vasodilation (Group II); similarly, right ventricular stroke work index was preserved at a lower right ventricular filling pressure in patients in Group I than in those in Group II. Although both groups improved clinically, patients in whom pulmonary arteriolar resistance decreased during converting enzyme inhibition had less dramatic decreases in systemic blood pressure (and thus experienced less symptomatic hypotension) and had a greater decrease in body weight during treatment (presumably due to a drug-induced natriuresis) than did patients who showed primarily systemic vasodilator effects and in whom sodium excretion may have been limited by the hypotensive effects of the drug (28, 29) ; this natriuresis may have contributed significantly to the substantial decrease in central venous pressures seen in patients in Group I. These data strongly support the concept that the pulmonary circulation modulates changes in both right and left ventricular performance during vasodilator therapy in patients with left heart failure.
Role of the pulmonary circulation in left ventricular failure. Clinicians have long believed that excessive elevation of systemic vascular resistance is the principal hemodynamic abnormality of patients with congestive heart failure and is responsible for their depressed left ventricular function and the severity of their symptoms. Recent studies (10,11) have shown, however, that right ventricular ejection fraction and pulmonary arteriolar resistance are important determinants of the functional status of patients with left heart failure and correlate better with exercise capacity than do measures of left ventricular performance. In such patients, the ability to increase cardiac output during exertion is the primary determinant of exercise duration; if this ability is limited by heightened pulmonary arteriolar resistance or by right ventricular dysfunction, cardiac output may not increase sufficiently to meet the metabolic requirements of the body, even if systemic vascular resistance decreases dramatically (10) . Furthermore, systemic vasodilation in the absence of pulmonary vasodilation may result in severe hypotension. Such hypotensive episodes are well known in patients with pulmonary hypertension secondary to obliterative pulmonary vascular disease whose pulmonary vessels are unable to respond to systemic vasodilator therapy (25, 26) ; our data indicate that similar hemodynamic events may explain the hypotensive symptoms of patients with left ventricular failure treated with vasodilator drugs. If, on the other hand, pulmonary vasodilation does occur during long-term therapy, right ventricular performance may improve dramatically and result in an increase in cardiac output and exercise capacity (I 2).
Limited pulmonary vasodilator effects of angiotensin suppression. A desired goal of vasodilator therapy for patients with left ventricular failure, therefore, is balanced systemic and pulmonary vasodilation. Direct-acting vasodilator drugs (such as nitroprusside and nitrates) decrease systemic and pulmonary resistances to a similar degree (13) (14) (15) , but converting enzyme inhibition generally produces dilation in the pulmonary circulation far less dramatically than it does in the systemic circuit (21, 22) . These observations are consistent with the fact that angiotensin is a potent systemic vasoconstrictor that exerts little direct action on the pulmonary vessels in physiologic concentrations (16, 20) ; thus, neutralization of its effects during captopril therapy produces minimal pulmonary vasodilation. Previous studies have established the limited pulmonary vascular effects of captopril during short-term therapy (21,22) ; the present findings extend these observations to long-term treatment. These observations may explain why right ventricular stroke work failed to increase during converting enzyme inhibition in our 75 patients, even though left ventricular stroke work increased significantly as resistance to left ventricular systolic ejection decreased. These discordant responses probably account for the greater frequency of symptomatic hypotension with captopril compared with other vasodilator drugs (l ,21). Furthermore, the limited ability of captopril to improve right ventricular function may restrict the potential of some patients to benefit from converting enzyme inhibition. Patients with poor right ventricular function do not respond well to captopril therapy (30, 31) , and pretreatment right ventricular function appears to be the principal determinant of long-term survival in patients with left heart failure treated with converting enzyme inhibitors (31,32).
Mechanisms of pulmonary vasodilation during captopril therapy. The mechanisms just outlined logically explain why our patients with the highest pretreatment plasma renin activity and the lowest serum sodium concentration showed the least pulmonary vasodilation during long-term therapy with captopril. These patients have the greatest activation of the renin-angiotensin system and appear to be highly dependent on angiotensin II to support circulatory homeostasis (33) ; interference with angiotensin II formation, therefore, can be expected to result in dramatic systemic (but not pulmonary) vasodilation and symptomatic hypotension (34) , the severity of which is likely to be potentiated by the limited pulmonary vascular responses seen in this group (25) . Such mechanisms, however, fail to account for the marked and balanced pulmonary and systemic vasodilation during long-term therapy with captopril in our patients in Group I, who generally had a low plasma renin activity. Why should captopril have resulted in dramatic hemodynamic and clinical benefits in these patients? Converting enzyme inhibition may produce hemodynamic improvement in some patients with low renin heart failure by further reducing the low (but potentially still physiologically important) levels of circulating angiotensin II (35) . If withdrawal of the actions of angiotensin were the only mechanism of action in these patients, however, we would have expected their pulmonary and systemic vasodilator responses to captopril to be similar to those seen in our high renin patients; because the reverse was true, we must postulate other mechanisms to explain our observations. The angiotensin-converting enzyme is also the same enzyme responsible for the degradation of endogenous kinins (36) , which exert potent vasodilating effects by their ability to stimulate the production of prostaglandins by the kidney lACC Vol. 6, NO.3 September 1985:635-45 (37, 38) . Hence, by inhibiting the converting enzyme, captopril may retard kinin metabolism and thereby enhance prostaglandin synthesis, which may contribute substantially to the circulatory effects of the drug. That these concepts have therapeutic significance is supported by clinical data showing I) a marked increase in the level of prostaglandin E metabolites in the urine of patients with hypertension and heart failure treated with captopril (39-41), and 2) attenuation of the effects of captopril in hypertensive patients by agents that inhibit prostaglandin synthesis (40) . Studies by two independent groups of investigators (42, 43) have concluded that prostaglandins play the major role in mediating the therapeutic effects of converting enzyme inhibition in patients with a low plasma renin activity; in contrast, arachidonic acid metabolites appear to have little significance in patients with marked activation of the reninangiotensin system.
Our findings provide circumstantial support for the hypothesis that prostaglandins may mediate some of the hemodynamic effects of captopril in patients with low renin heart failure. In our patients in Group I (predominant pulmonary vasodilation) whose average plasma renin activity was only 3.0 ± 0.6 ng/ml per h, captopril produced marked decreases in both pulmonary and systemic vascular resistance, a response that is more consistent with the known hemodynamic effects of prostaglandin E than the events expected to follow interference with the renin-angiotensin system; unlike angiotensin II, prostaglandin E (particularly E 1 ) has direct actions on the pulmonary circulation (44, 45) and produces balanced systemic and pulmonary vasodilator effects in patients with congestive heart failure (46). Furthermore, production of prostaglandins by the kidney may contribute significantly to the increase in plasma renin activity that follows converting enzyme inhibition (43, 47) , which may explain why reactive hyperreninemia was most marked in patients with the greatest pulmonary vasodilator responses. The enhanced synthesis of renal prostaglandins may serve to potentiate the effects of furosemide (8, 43) , which may also be mediated by prostaglandin E intermediates (48-50); this hormonal interaction may account for the diuresis seen in patients in Group I. Further research is needed to validate these concepts; such studies should include both measurement of prostaglandin metabolites and hemodynamic assessment of the effects of inhibitors of prostaglandin synthesis during treatment with captopril to determine whether these hormonal and hemodynamic events correlate with the magnitude of pulmonary vasodilation. It is also possible that other hormonal events (for example, the reduction in circulating levels of catecholamines and vasopressin that accompanies long-term converting enzyme inhibition [51] [52] [53] ) may contribute significantly to the hemodynamic responses we observed.
Limitations of the study. Our findings need to be interpreted in the context of certain precautions and limitations. We attempted to measure changes in vessel tone and caliber in the pulmonary circulation by calculating pulmonary arteriolar resistance, but conventional approaches to the measurement of this variable may not be accurate, because the relation between blood flow and resistance in the pulmonary circulation may not be linear (54, 55) . Furthermore, df4g-induced changes in left atrial pressure may induce secondary alterations in pulmonary arteriolar resistance in the absence of any direct pulmonary vasodilating action (56, 57) ; this observation is unlikely to have explained the different pulmonary vascular responses seen in patients in Groups I and II, however, because the groups demonstrated similar decreases in left ventricular filling pressure. An increase in pulmonary blood flow (secondary to an increase in cardiac output) can itself lower pulmonary resistance by the passive recruitment of unused vascular channels rather than by a direct active pulmonary vasodilating effect of a drug (58) . All of these passive components of the pulmonary vascular response may interact with active pulmonary vasodilation to determine the hemodynamic effects of therapy.
Despite these complexities, we believe that selective pulmonary vasodilation can be assumed to have occurred if the decrease in resistance in the pulmonary circulation exceeds that seen in the systemic circulation; this generally occurs when pulmonary arteriolar resistance decreases simultaneously with an increase in cardiac output and a decrease in mean pulmonary artery pressure (27) . Because the changes in all three variables were greater in patients in Group I (predominant pulmonary vasodilation) than in Group II (predominant systemic vasodilation), we believe that the greater decrease in pulmonary arteriolar resistance in patients in Group I was the result of active pulmonary vasodilation, a response that is difficult to explain on the basis of angiotensin II suppression alone.
We considered the possibility that our patients in Group II (predominant systemic vasodilation) did not show an active pulmonary vasodilator response during treatment with captopril because they had fixed structural disease of the pulmonary vasculature. Such pulmonary vascular obliteration may occur in patients who have long-standing increases in pulmonary venous pressure (with secondary fibrosis and hemosiderosis), particularly in those with severe mitral stenosis. The degrees of elevation of pulmonary arteriolar resistance in Groups I and II, were similar, however; we would have anticipated higher levels of pulmonary resistance for similar levels of left ventricular filling pressure if additional structural changes in the pulmonary vessels had developed in patients in Group II. Most important, the selective decrease in pulmonary arteriolar resistance after nitroglycerin administration in our patients in Group II strongly supports our hypothesis that the increased pulmonary resistance in these patients was the result of active pulmonary vasoconstriction that was still responsive to vasodilator therapy (Table 4).
Finally, it is possible that patients in Group II did not show substantial pulmonary vasodilation because treatment PACKER ET AL.
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PULMONARY VASODILATION IN HEART FAILURE with captopril activated endogenous vasoconstrictor forces that selectively antagonized the pulmonary vasodilation that might have been expected to accompany any drug-induced decrease in left ventricular filling pressures. The activation of such forces has been shown to limit the systemic effect of other vasodilator drugs in patients with severe chronic heart failure (59, 60) . There is little evidence, however, that such forces are activated during long-term treatment with captopril. Circulating levels of both catecholamines and vasopressin decrease during long-term captopril therapy (51-53); these additional hormonal changes may contribute significantly to the hemodynamic improvement as well as to the decreases in heart rate and the correction of hyponatremia that follow the converting enzyme inhibition in these patients (8, 9) . Furthermore, neither norepinephrine nor vasopressin is known to selectively constrict the pulmonary vasculature. Consequently, selective reflex vasoconstriction is an unlikely explanation for our findings.
Conclusions. The present study indicates that the pulmonary circulation plays an important role in modifying the hemodynamic responses seen during long-term angiotensinconverting enzyme inhibition in patients with severe chronic heart failure. Patients with hyponatremia and a high plasma renin activity generally show little long-term pulmonary vasodilator response to captopril; therefore, because the patients' ability to increase cardiac output is limited, clinical and hemodynamic benefits are achieved at the cost of frequent episodes of symptomatic hypotension. On the other hand, some patients with low renin heart failure show marked pulmonary vasodilator effects during treatment that dramatically el1hance the improvement in left ventricular performance that might be expected to accompany any druginduced decrease in systemic vascular resistance without additional hypotensive risk; such pulmonary vasodilator effects are difficult, however, to explain on the basis of angiotensin suppression alone. These observations suggest that some patients with severe chronic heart failure may benefit from long-term captopril therapy through mechanisms independent of interference with the renin-angiotensin system.
